Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection

Completed

• Conditions: Acinetobacter Baumannii Infection
• Interventions: Other: None intervention

• Registration Number: NCT02886637
• Lead Sponsor: Southeast University, China

Brief Summary

The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.

Detailed Description

This is a single-center, observational study. Patients with Acinetobacter baumannii infection in the intensive care unit of Zhongda Hospital were enrolled. We recorded the data of age, ICU admission diagnosis, underlying diseases, APACHE II score and infection site. Body temperature, heart rate, white blood cell counts, procalcitonin, C-reactive protein, SOFA score and the level of CD4+, CD8+, Th1, Th2 and HLA-DR in the blood measured by flow cytometry on the D1, D3 and D7 were also recorded.We can get the results of the change of immune function of critical ill patients after Acinetobacter baumannii infection. After compare the patients who die of survive at 28 day after infection, we can get the results of the relationship between the immune function and the outcome. We also can calculate the effect immune function on prognositic mortality in patients with Acinetobacter baumannii infection.

Study Timeline

• Study Start: 2015-07
• Primary Completion: 2016-03
• Study Completion: 2016-03
• Status Verified: 2016-08
• Study First Submitted: 2016-08-27
• Study First Submitted QC: 2016-08-31
• Last Update Submitted: 2016-08-31
• Study First Posted: 2016-09-01
• Last Update Posted: 2016-09-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Patients admitted to ICU
• Infection with Acinetobacter baumannii
• Agree to participate the study

Exclusion Criteria

• Age less than 16 years old or older than 80 years old

• pregnancy

• immunosuppression patients which include

  1. therapy 0.5mg/kg/day of prednisoneover(equivalent dose of other glucocorticoids) for at least 1 month within recent 3 month
  2. Cancer chemotherapy within recent 3 month
  3. Receive immunosuppression treatment because of solid organ transplant or Autoimmune diseases
  4. allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation.
  5. HIV infection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Acinetobacter baumannii infection	None intervention	Critically ill patients infect with Acinetobacter baumannii

Primary Outcome Measures

Name	Time	Method
28 day mortality	28 day